Day: November 9, 2019

NC318 was well toleratedSingle agent activity observed in multiple tumor types, including a CR and a PR in NSCLCInitiated Phase 2 portion of the Phase 1/2 monotherapy trial and plans for a combo trial with standard of care chemotherapiesBELTSVILLE, Md., Nov. 09, 2019 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that updated clinical results from the Phase 1 portion of its ongoing trial with NC318, a monoclonal antibody targeting Siglec-15 (S15), were presented at the SITC annual meeting. S15 is a novel immunomodulatory protein that is expressed on highly immunosuppressive cells called M2 macrophages and on tumor cells. In addition, NextCure...

SALT LAKE CITY, Nov. 09, 2019 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in precision medicine, announced that its Myriad Autoimmune business unit will present new data on the Vectra test at the 2019 ACR/ARP Annual Meeting being held Nov. 8-13, 2019 in Atlanta, GA.  The key findings are that the Vectra test predicts the risk of radiographic progression (RP) within one year, and the Vectra score, in combination with other clinical measures, predicts the risk of a cardiovascular (CV) event in people with rheumatoid arthritis (RA).“A hallmark feature of rheumatoid arthritis is inflammation, which increases the risk of joint damage, cardiovascular disease and other comorbidities,” said Elena Hitraya, M.D., Ph.D., rheumatologist and chief medical officer at Myriad Autoimmune. “The data being presented by...

— Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease Modifying Antirheumatic Drug(s) (csDMARDs) —— Data Demonstrate Efficacy and Safety Across a Wide Range of Patient Populations, Including Those Intolerant or Unresponsive to Biologic Treatment —— Data to be Presented at 2019 ACR/ARP Annual Meeting —Foster City, Calif., and Mechelen, Belgium, November 9, 2019, 22.30 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the companies’ clinical research program evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely...

— Analyse van alle gegevens in het klinische FINCH RA-programma staaft het gunstige veiligheids- en tolerantieprofiel van kandidaatgeneesmiddel filgotinib, zowel in monotherapie als in combinatie met methotrexaat (MTX) of bestaande reumamedicjjnen  (de zgn. DMARD’s) —— Gegevens tonen werkzaamheid en veiligheid aan in een breed scala aan patiëntenpopulaties, inclusief bij patiënten die intolerant zijn voor, of niet reageren op, een behandeling met biologische medicijnen–— Data worden gepresenteerd op jaarvergadering 2019 van ACR/ARP —Foster City, California, en Mechelen, België, 9 november 2019, 22.30 CET – Gilead Sciences, Inc. (Nasdaq: GILD) en Galapagos NV (Euronext & NASDAQ: GLPG) maakten vandaag gedetailleerde resultaten bekend van hun klinische onderzoeksprogramma naar filgotinib, een experimentele,...

ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccinationInhibitory T cell responses exacerbate tumor growthCAMBRIDGE, Mass., Nov. 09, 2019 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented clinical and preclinical data demonstrating the potential of Genocea’s unique, biology-driven ATLAS platform to select neoantigens for inclusion in anti-tumor immunotherapies. Striking clinical evidence shows that the presence of inhibitory neoantigens in an otherwise protective therapeutic vaccine completely suppressed anti-tumor immune responses and promoted tumor growth in pre-clinical models. These data were presented at the 34th Annual Meeting of the Society for Immunotherapy...

ROCHESTER, N.Y., Nov. 09, 2019 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim data of the Phase 1b/2 study of pepinemab in combination with anti-PD-L1 checkpoint inhibitor, BAVENCIO® (avelumab), in non-small cell lung cancer (NSCLC) is being reported during a poster presentation on Saturday, November 9 at the 34th Annual Meeting of The Society for Immunotherapy of Cancer (“SITC”).   Below is a summary of updated interim data from the poster presentation.Updated Interim DataThe CLASSICAL-Lung trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany.  It is a multi-center, open-label study designed to evaluate the safety and potential efficacy of...

LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today presented pre-clinical data on AUTO6NG, the company’s next generation GD2-targeting CAR (chimeric antigen receptor) T cell therapy, at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 6-10, 2019, in Washington, D.C.“Autolus’ growing set of programming modules ​addresses a range of inhibitory factors within the highly complex and dynamic solid tumor microenvironment​.  This presentation demonstrates the utility of three modules added to the clinically active and validated AUTO6 GD-2 targeting CAR that not only improve CAR T persistence but also combat the immunosuppressive environment,”...

Telefonkonferenz und Webcast am Freitag, den 8. November um 14:30 Uhr MEZ 20:30 Uhr ETTRYbeCA1, Phase-3-Studie mit Eryaspase als Zweitlinienbehandlung bei Bauchspeicheldrüsenkrebs:positive Sicherheitsüberprüfung durch ein unabhängiges Datenüberwachungskomiteefür Patienteneinschreibung in den USA eröffneterste klinische Standorte in den USA aktiviertProduktionsstätte in Princeton bereit für die Herstellung von klinischen ChargenCash-Position von 81,9 Mio. € (89,2 Mio. USD) per Ende SeptemberLYON, Frankreich und CAMBRIDGE, Massachusetts, Nov. 09, 2019 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), ist ein in der klinischen Entwicklungsphase tätiges Biopharma-Unternehmen, das innovative Therapien entwickelt, indem es therapeutische Wirkstoffe in rote Blutkörperchen einkapselt, hat heute ein Business Update vorgelegt...

TRYbeCA1, trial clinico di fase 3 relativo all’eryaspase per il trattamento di seconda linea del carcinoma pancreatico:valutazione positiva della sicurezza da parte di un comitato indipendente per il monitoraggio dei datiiniziato il reclutamento dei pazienti negli Stati Unitiattivati i primi siti clinici negli Stati UnitiLo stabilimento di produzione di Princeton è pronto per la produzione di lotti cliniciPosizione finanziaria di €81,9 milioni ($89,2 milioni) alla fine di settembreLIONE, Francia e CAMBRIDGE, Mass., Nov. 09, 2019 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), un’azienda biofarmaceutica in fase clinica che sviluppa terapie innovative incapsulando sostanze farmacologiche all’interno dei globuli rossi, ha presentato oggi un business update e i risultati finanziari relativi al trimestre...

Following the first full year of legalization, over 31,000 consumer votes on lift.co determined the top cannabis flower and oil products of 2019Innovation of the Year goes to Solei Renew CBN Oil7ACRES wins Brand of the Year for the second year in a rowSuperette sweeps the newly added retail categories winning Top Retail Store—Single Location and Top Budtender, as well as Startup of the Year; Co-founder and CEO Mimi Lam wins Womxn in Weed-TrailblazerTORONTO, Nov. 08, 2019 (GLOBE NEWSWIRE) — Three weeks following the first anniversary of legalization, Lift & Co. (the “Company”) (TSXV: LIFT) (OTCQB: LFCOF) tonight announced the top cannabis people, brands, organizations and products of 2019 at the sixth annual Canadian Cannabis Awards (“CCAs”) as selected by consumers and industry experts. A total of 32 awards were...